Dr. Postow on BRAF and MEK Inhibitor Combination Studies in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

There are 2 BRAF and MEK studies for patients with stage III resected melanoma. The BRIM8 study investigated vemurafenib (Zelboraf) versus placebo, states Postow. The other study is the COMBI-AD study, which investigated dabrafenib (Tafinlar) plus trametinib (Mekinist) versus placebo for patients with stage III resected melanoma.

According to Postow, both studies had interesting biologic effects demonstrating efficacy.

<<< View more from the World Congress of Melanoma